In a small group of people with severe inherited high cholesterol who were already on maximum medication, one dose of an experimental gene-editing treatment led to measurable drops in PCSK9 and LDL cholesterol levels, with no severe side effects observed.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether VERVE-102 or similar PCSK9 base-editing therapies consistently reduce LDL cholesterol and cardiovascular events across multiple controlled trials in diverse populations.
A systematic review and meta-analysis of all completed randomized controlled trials comparing VERVE-102 or similar PCSK9 base editors to placebo or standard care in adults with heterozygous familial hypercholesterolemia or established coronary artery disease, measuring LDL-C reduction at 12, 24, and 52 weeks, and major adverse cardiovascular events over 3 years.
Whether VERVE-102 causes a clinically meaningful reduction in LDL cholesterol compared to placebo in patients with heterozygous familial hypercholesterolemia.
A double-blind, placebo-controlled, multicenter trial of 150 adults aged 18–65 with heterozygous familial hypercholesterolemia and LDL-C ≥100 mg/dL despite maximally tolerated statins and ezetimibe, randomized 1:1 to receive a single IV infusion of VERVE-102 (dose determined from Heart-2) or saline placebo, with primary outcome of percent change in LDL-C at 24 weeks measured by fasting lipid panel.
Whether individuals treated with VERVE-102 experience sustained LDL-C reduction and lower rates of cardiovascular events over 5 years compared to matched untreated controls.
A prospective cohort study following 500 individuals with heterozygous familial hypercholesterolemia who received VERVE-102 in phase 2 trials, matched 1:2 with untreated controls by age, sex, baseline LDL-C, and cardiovascular risk factors, tracking LDL-C levels annually and major cardiovascular events over 5 years.
Whether individuals who experienced serious adverse events after VERVE-102 administration had different baseline genetic or metabolic profiles than those who did not.
A nested case-control study within a phase 2 cohort comparing 30 individuals who developed hepatotoxicity or off-target editing events within 1 year of VERVE-102 infusion to 90 matched controls without such events, analyzing whole-genome sequencing, lipidomics, and immune markers.
Whether individual patients with rare genetic variants show unexpected responses to VERVE-102, such as unusually high or low editing efficiency.
Detailed reporting of 10–20 individual cases of patients with heterozygous familial hypercholesterolemia who received VERVE-102 and exhibited extreme PCSK9 editing efficiency (>90% or <10%) or unexpected lipid responses, including pre- and post-treatment sequencing and lipid profiles.